The Ozempic label calls the delay minor and counts it as part of how the drug lowers blood sugar after meals.1,2,3,4 A 2024 review measured the delay for solid meals at about 36 minutes on average.5
How much it slows
The review pooled 15 studies of GLP-1 medicines that measured gastric emptying.5
- Solid meals, by scan. In five studies with 247 participants using a gastric emptying scan, the time for half the meal to leave the stomach was 138.4 minutes on a GLP-1 medicine and 95.0 minutes on placebo. The difference was 36.0 minutes, with a confidence interval from 17.0 to 55.0.
- Liquids, by absorption test. In ten studies with 411 participants using the acetaminophen absorption test, the delay did not reach statistical significance.
- No clear pattern by drug. Short-acting or long-acting, and how long people had taken it, did not change the result.
The authors concluded that a delay of about 36 minutes is measurable and of limited size compared with the usual fasting periods before procedures.5
How it is measured
NIDDK describes three tests. In a gastric emptying scan, the person eats a bland meal such as eggs containing a small amount of radioactive material, and a camera tracks it, usually for about 4 hours, or 240 minutes. In a breath test, the meal contains a substance that is absorbed in the intestines and passes into the breath, and breath samples are collected over about 4 hours. A wireless motility capsule, swallowed like a pill, reports how fast the stomach empties and how food moves through the intestines.6 The 2022 gastroenterology guideline names the scan as the standard test, followed for three hours or more, and counts more than 10% of a standard egg meal still in the stomach at 4 hours as delayed.7
Does it fade over time?
For tirzepatide, the Zepbound and Mounjaro labels say the delay is largest after the first dose and diminishes over time.3,4 The study behind that statement, run by the drug's maker, found the effect diminished after several doses in healthy volunteers, while a residual delay remained in people with type 2 diabetes on a rising dose.8 For semaglutide 2.4 mg, a 20-week trial measured emptying with paracetamol, a liquid-phase test, and found no evidence of slower emptying than on placebo at week 20.9 A 2021 review describes this fading as tachyphylaxis and notes it with the long-acting medicines.10
Why it matters
- Fullness and nausea. A slower stomach is one reason people feel full sooner and why large or fatty meals can bring on nausea; the nutrition advisory for these medicines recommends small meals.11
- Pills taken by mouth. The Mounjaro label warns that slower emptying may affect the absorption of other oral medicines, including birth control pills.4
- Anesthesia. Food can remain in the stomach at the time of surgery; the labels report rare cases of aspiration.3
Slower is not the same as gastroparesis
None of these studies diagnosed gastroparesis; they measured emptying in volunteers and trial participants taking the drugs, which is a different question. Gastroparesis is a disorder defined by objective delay without a blockage, together with symptoms, and a 2025 analysis of 55 trials found that GLP-1 medicines probably have little or no effect on its risk.7,12 Our page on Ozempic and gastroparesis covers that question in full.
Sources
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 5, 6.2, 7, 12 and 17. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 5, 6.2, 7 and 12. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
- Hiramoto B, McCarty TR, Lodhia NA, et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. Am J Gastroenterol 2024;119:1126-1140. doi:10.14309/ajg.0000000000002820
- National Institute of Diabetes and Digestive and Kidney Diseases. Gastroparesis: Definition and Facts; Symptoms and Causes; Diagnosis; Treatment; Eating, Diet, and Nutrition. Last reviewed January 2018, read November 20, 2026. niddk.nih.gov
- Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol 2022;117:1197-1220. doi:10.14309/ajg.0000000000001874
- Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab 2020;22:1886-1891. doi:10.1111/dom.14110
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754-762. doi:10.1111/dom.14280
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 2021;46:101102. doi:10.1016/j.molmet.2020.101102
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
- Chiang CH, Jaroenlapnopparat A, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology 2025;169:1268-1281. doi:10.1053/j.gastro.2025.06.003
Related analyses
Ozempic and gastroparesis: what the stomach paralysis studies found
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Burping, reflux and gas on a GLP-1: how common, why, and what helps
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Log meals, fullness and nausea with your doses, and see whether big meals are the trigger.
Open Dose Insider